Oncopeptides AB (publ) (STO:ONCO)

Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of SEK 502.01 million. The enterprise value is 568.99 million.

Market Cap	502.01M
Enterprise Value	568.99M

Important Dates

The last earnings date was Tuesday, April 28, 2026.

Earnings Date	Apr 28, 2026
Ex-Dividend Date	n/a

Share Statistics

Oncopeptides AB has 395.29 million shares outstanding. The number of shares has increased by 36.32% in one year.

Current Share Class	381.15M
Shares Outstanding	395.29M
Shares Change (YoY)	+36.32%
Shares Change (QoQ)	+15.59%
Owned by Insiders (%)	0.46%
Owned by Institutions (%)	10.04%
Float	379.33M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.06
PB Ratio	-8.52
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.28
EV / Sales	8.00
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.63

Current Ratio	2.63
Quick Ratio	2.45
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-9.55

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-74.09%
Return on Invested Capital (ROIC)	-98.07%
Return on Capital Employed (ROCE)	-248.68%
Weighted Average Cost of Capital (WACC)	0.10%
Revenue Per Employee	948,240
Profits Per Employee	-3.33M
Employee Count	75
Asset Turnover	0.38
Inventory Turnover	0.39

Taxes

In the past 12 months, Oncopeptides AB has paid 1.42 million in taxes.

Income Tax	1.42M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.22% in the last 52 weeks. The beta is -1.42, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-1.42
52-Week Price Change	-32.22%
50-Day Moving Average	1.53
200-Day Moving Average	3.92
Relative Strength Index (RSI)	35.96
Average Volume (20 Days)	2,903,790

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of SEK 71.12 million and -249.59 million in losses. Loss per share was -1.10.

Revenue	71.12M
Gross Profit	68.67M
Operating Income	-224.65M
Pretax Income	-248.17M
Net Income	-249.59M
EBITDA	-222.18M
EBIT	-224.65M
Loss Per Share	-1.10

Balance Sheet

The company has 82.26 million in cash and 149.23 million in debt, with a net cash position of -66.97 million or -0.17 per share.

Cash & Cash Equivalents	82.26M
Total Debt	149.23M
Net Cash	-66.97M
Net Cash Per Share	-0.17
Equity (Book Value)	-58.89M
Book Value Per Share	-0.22
Working Capital	72.66M

Cash Flow

Operating Cash Flow	-216.49M
Capital Expenditures	n/a
Depreciation & Amortization	2.47M
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	96.55%
Operating Margin	-315.88%
Pretax Margin	-348.96%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-36.32%
Shareholder Yield	-36.32%
Earnings Yield	-49.72%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3